Compass Pathways soars on second Phase 3 depression hit
Compass Pathways因第二项三期抑郁症试验再获成功而大涨

The second pivotal trial of Compass Pathways’ psilocybin formulation for treatment-resistant depression has succeeded, the company said Tuesday, a result that could help the drug gain approval next year.
该公司周二表示，Compass Pathways用于治疗难治性抑郁症的裸盖菇素制剂的第二项关键性试验已告成功，这一结果或将助其药物在明年获批。